Visceral adipose tissue-derived serine protease inhibitor inhibits interleukin-1β-induced catabolic and inflammatory responses in murine chondrocytes

Molecular Medicine Reports

Volumn 10, Issue 4, 2014, Pages 2191-2197

  Bao, Jia Peng ^a   Jiang, Li Feng ^a   Li, Jing ^a   Chen, Wei Ping ^a   Hu, Peng Fei ^a   Wu, Li Dong ^a  

^a ZHEJIANG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

Chondrocytes; Osteoarthritis; Vaspin

Indexed keywords

AGGRECANASE 1; AGGRECANASE 2; ANTIINFLAMMATORY AGENT; CATHEPSIN D; CYCLOOXYGENASE 2; GELATINASE A; GELATINASE B; I KAPPA B ALPHA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INDUCIBLE NITRIC OXIDE SYNTHASE; INTERLEUKIN 1BETA; PROSTAGLANDIN E2; VASPIN; ADAM PROTEIN; ADAMTS4 PROTEIN, RAT; ADAMTS5 PROTEIN, RAT; ADIPOCYTOKINE; I KAPPA B; NF-KAPPAB INHIBITOR ALPHA; NOS2 PROTEIN, RAT; PTGS2 PROTEIN, RAT; SERINE PROTEINASE INHIBITOR; VASPIN PROTEIN, MOUSE;

ANIMAL CELL; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CARTILAGE CELL; CATABOLISM; CELL METABOLISM; CELL PROLIFERATION; CELL VIABILITY; CYTOTOXICITY; GENE EXPRESSION; NONHUMAN; OSTEOARTHRITIS; PATHOPHYSIOLOGY; PROTEIN DEGRADATION; PROTEIN PHOSPHORYLATION; RAT; ANIMAL; CELL CULTURE; CELL SURVIVAL; CYTOLOGY; DRUG EFFECTS; GENETICS; METABOLISM; PHOSPHORYLATION; SIGNAL TRANSDUCTION; SPRAGUE DAWLEY RAT;

ADAM PROTEINS; ADIPOKINES; ANIMALS; CATHEPSIN D; CELL SURVIVAL; CELLS, CULTURED; CHONDROCYTES; CYCLOOXYGENASE 2; DINOPROSTONE; I-KAPPA B PROTEINS; INTERLEUKIN-1BETA; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE 9; NF-KAPPA B; NITRIC OXIDE SYNTHASE TYPE II; PHOSPHORYLATION; RATS; RATS, SPRAGUE-DAWLEY; SERPINS; SIGNAL TRANSDUCTION;

EID: 84929515085     PISSN: 17912997     EISSN: 17913004     Source Type: Journal    
DOI: 10.3892/mmr.2014.2478     Document Type: Article

References (43)

1. Krasnokutsky S, Samuels J and Abramson SB: Osteoarthritis in 2007. Bull NYU Hosp Jt Dis 65: 222-228, 2007. (Pubitemid 351412136)
2. Kapoor M, Martel-Pelletier J, Lajeunesse D, Pelletier JP and Fahmi H: Role of proinflammatory cytokines in the pathophysiology of osteoarthritis. Nat Rev Rheumatol 71: 33-42, 2011.
3. Goldring MB and Goldring SR: Osteoarthritis. J Cell Physiol 213: 626-634, 2007. (Pubitemid 350058254)
4. Yusuf E: Metabolic factors in osteoarthritis: obese people do not walk on their hands. Arthritis Res Ther 14: 123, 2012.
5. Cicuttini FM, Baker JR and Spector TD: The association of obesity with osteoarthritis of the hand and knee in women: a twin study. J Rheumatol 23: 1221-1226, 1996.
6. Yusuf E: Metabolic factors in osteoarthritis: obese people do not walk on their hands. Arthritis Res Ther 14: 123, 2012.
7. Bay-Jensen AC, Slagboom E, Chen-An P, et al: Role of hormones in cartilage and joint metabolism: understanding an unhealthy metabolic phenotype in osteoarthritis. Menopause 20: 578-586, 2013.
8. Hida K, Wada J, Eguchi J, et al: Visceral adipose tissue-derived serine protease inhibitor: a unique insulin-sensitizing adipocytokine in obesity. Proc Natl Acad Sci USA 102: 10610-10615, 2005. (Pubitemid 41061602)
9. Fain JN, Buehrer B, Bahouth SW, Tichansky DS and Madan AK: Comparison of messenger RNA distribution for 60 proteins in fat cells vs the nonfat cells of human omental adipose tissue. Metabolism 57: 1005-1015, 2008. (Pubitemid 351814693)
10. Klöting N, Berndt J, Kralisch S, et al: Vaspin gene expression in human adipose tissue: association with obesity and type 2 diabetes. Biochem Biophys Res Commun 339: 430-436, 2006. (Pubitemid 41697566)
11. Meyer-Hoffert U: Reddish, scaly, and itchy: how proteases and their inhibitors contribute to inflammatory skin diseases. Arch Immunol Ther Exp (Warsz) 57: 345-354, 2009.
12. Klöting N, Kovacs P, Kern M, et al: Central vaspin administration acutely reduces food intake and has sustained blood glucose-lowering effects. Diabetologia 54: 1819-1823, 2011.
13. Körner A, Neef M, Friebe D, et al: Vaspin is related to gender, puberty and deteriorating insulin sensitivity in children. Int J Obes (Lond) 35: 578-586, 2011.
14. Youn BS, Klöting N, Kratzsch J, et al: Serum vaspin concentrations in human obesity and type 2 diabetes. Diabetes 57: 372-377, 2008.
15. Ozgen M, Koca SS, Dagli N, Balin M, Ustundag B and Isik A: Serum adiponectin and vaspin levels in rheumatoid arthritis. Arch Med Res 41: 457-463, 2010.
16. Klaasen R, Herenius MM, Wijbrandts CA, et al: Treatment-specific changes in circulating adipocytokines: a comparison between tumour necrosis factor blockade and glucocorticoid treatment for rheumatoid arthritis. Ann Rheum Dis 71: 1510-1516, 2012.
17. Senolt L, Polanská M, Filková M, et al: Vaspin and omentin: new adipokines differentially regulated at the site of inflammation in rheumatoid arthritis. Ann Rheum Dis 69 1410-1411, 2010.
18. Kamio N, Kawato T, Tanabe N, et al: Vaspin attenuates RANKL-induced osteoclast formation in RAW264.7 cells. Connect Tissue Res 54: 147-152, 2013.
19. Choi SH, Hong ES and Lim S: Clinical implications of adipocytokines and newly emerging metabolic factors with relation to insulin resistance and cardiovascular health. Front Endocrinol (Lausanne) 4: 97, 2013.
20. Wada J: Vaspin: a novel serpin with insulin-sensitizing effects. Expert Opin Investig Drugs 17: 327-333, 2008.
21. Kadoglou NP, Gkontopoulos A, Kapelouzou A, et al: Serum levels of vaspin and visfatin in patients with coronary artery disease-Kozani study. Clin Chim Acta 412: 48-52, 2011.
22. Phalitakul S, Okada M, Hara Y and Yamawaki H: Vaspin prevents methylglyoxal-induced apoptosis in human vascular endothelial cells by inhibiting reactive oxygen species generation. Acta Physiol (Oxf) 209: 212-219, 2013.
23. Phalitakul S, Okada M, Hara Y and Yamawaki H: Vaspin prevents TNF-α-induced intracellular adhesion molecule-1 via inhibiting reactive oxygen species-dependent NF-κB and PKCθ activation in cultured rat vascular smooth muscle cells. Pharmacol Res 64: 493-500, 2011.
24. Kukla M, Mazur W, Bułdak RJ and Zwirska-Korczala K: Potential role of leptin, adiponectin and three novel adipokines - visfatin, chemerin and vaspin - in chronic hepatitis. Mol Med 17: 1397-1410, 2011.
25. Fu BD, Yamawaki H, Okada M and Hara Y: Vaspin can not inhibit TNF-α-induced inflammation of human umbilical vein endothelial cells. J Vet Med Sci 71: 1201-1207, 2009.
26. Bao JP, Chen WP, Feng J, Hu PF, Shi ZL and Wu LD: Leptin plays a catabolic role on articular cartilage. Mol Biol Rep 37: 3265-3272, 2010.
27. Hu PF, Chen WP, Tang JL, Bao JP and Wu LD: Apelin plays a catabolic role on articular cartilage: in vivo and in vitro studies. Int J Mol Med 26: 357-363, 2010.
28. Uchida K, Urabe K, Naruse K, Ogawa Z, Mabuchi K and Itoman M: Hyperlipidemia and hyperinsulinemia in the spontaneous osteoarthritis mouse model, STR/Ort. Exp Anim 58: 181-187, 2009.
29. Chen TH, Chen L, Hsieh MS, Chang CP, Chou DT and Tsai SH: Evidence for a protective role for adiponectin in osteoarthritis. Biochim Biophys Acta 1762: 711-718, 2006. (Pubitemid 44293372)
30. Hsieh YS, Yang SF, Chu SC, et al: Expression changes of gelatinases in human osteoarthritic knees and arthroscopic debridement. Arthroscopy 20: 482-488, 2004.
31. Birkedal-Hansen H, Moore WG, Bodden MK, et al: Matrix metalloproteinases: a review. Crit Rev Oral Biol Med 4: 197-250, 1993. (Pubitemid 23103292)
32. Kozaci LD, Buttle DJ and Hollander AP: Degradation of type II collagen, but not proteoglycan, correlates with matrix metalloproteinase activity in cartilage explant cultures. Arthritis Rheum 40: 164-174, 1997. (Pubitemid 27044048)
33. Fushimi K, Troeberg L, Nakamura H, Lim NH and Nagase H: Functional differences of the catalytic and non-catalytic domains in human ADAMTS-4 and ADAMTS-5 in aggrecanolytic activity. J Biol Chem 283: 6706-6716, 2008.
34. Handley CJ, Mok MT, Ilic MZ, Adcocks C, Buttle DJ and Robinson HC: Cathepsin D cleaves aggrecan at unique sites within the interglobular domain and chondroitin sulfate attachment regions that are also cleaved when cartilage is maintained at acid pH. Matrix Biol 20: 543-553, 2001. (Pubitemid 33109102)
35. Chabane N, Zayed N, Afif H, et al: Histone deacetylase inhibitors suppress interleukin-1β-induced nitric oxide and prostaglandin E2 production in human chondrocytes. Osteoarthritis Cartilage 16: 1267-1274, 2008.
36. Salvemini D, Misko TP, Masferrer JL, Seibert K, Currie MG and Needleman P: Nitric oxide activates cyclooxygenase enzymes. Proc Natl Acad Sci USA 90: 7240-7244, 1993. (Pubitemid 23222425)
37. Sasaki K, Hattori T, Fujisawa T, Takahashi K, Inoue H and Takigawa M: Nitric xide mediates interleukin-1-induced gene expression of matrix metalloproteinases and basic fibroblast growth factor in cultured rabbit articular chondrocytes. J Biochem 123: 431-439, 1998. (Pubitemid 28143497)
38. Amin AR, Attur M, Patel RN, et al: Superinduction of cyclooxygenase -2 activity in human osteoarthritis-affected cartilage. Influence of nitric oxide. J Clin Invest 99: 1231-1237, 1997. (Pubitemid 27142759)
39. Wang P, Zhu F and Konstantopoulos K: Prostaglandin E2 induces interleukin-6 expression in human chondrocytes via cAMP/protein kinase A- and phosphatidylinositol 3-kinase-dependent NF-κB activation. Am J Physiol Cell Physio 298: C1445-C1456, 2010.
40. Vincenti MP and Brinckerhoff CE: Transcriptional regulation of collagenase (MMP-1, MMP-13) genes in arthritis: integration of complex signaling pathways for the recruitment of gene-specific transcription factors. Arthritis Res 4: 157-164, 2002. (Pubitemid 34460754)
41. Tian B and Brasier AR: Identification of a nuclear factor κB-dependent gene network. Recent Prog Horm Res 58: 95-130, 2003. (Pubitemid 37339306)
42. Hayden MS and Ghosh S: Signaling to NF-κB. Genes Dev 18: 2195-2224, 2004.
43. Li H, Peng W, Zhuang J, et al: Vaspin attenuates high glucose-induced vascular smooth muscle cells proliferation and chemokinesis by inhibiting the MAPK, PI3K/Akt, and NF-κB signaling pathways. Atherosclerosis 228: 61-68, 2013.